Signature Financial Management Inc. decreased its stake in Pfizer Inc. (NYSE:PFE) by 9.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,138 shares of the biopharmaceutical company’s stock after selling 7,205 shares during the period. Signature Financial Management Inc.’s holdings in Pfizer were worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Massachusetts Financial Services Co. MA lifted its holdings in shares of Pfizer by 0.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after purchasing an additional 160,730 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Pfizer by 2.5% in the second quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock valued at $1,972,442,000 after purchasing an additional 1,345,528 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Pfizer by 15.0% during the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after acquiring an additional 7,059,171 shares during the period. Fisher Asset Management LLC lifted its holdings in Pfizer by 4.4% during the second quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock worth $1,431,069,000 after acquiring an additional 1,671,311 shares during the period. Finally, LSV Asset Management lifted its holdings in Pfizer by 2.7% during the second quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock worth $1,334,182,000 after acquiring an additional 973,497 shares during the period. 69.42% of the stock is owned by institutional investors.
In other Pfizer news, major shareholder Pfizer Inc purchased 55,556 shares of Pfizer stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the acquisition, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by insiders.
Shares of NYSE:PFE opened at $45.14 on Thursday. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $46.47. The stock has a market cap of $268.71 billion, a P/E ratio of 17.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.88. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same quarter in the previous year, the business earned $0.67 EPS. Pfizer’s revenue was up 1.0% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.01%. Pfizer’s dividend payout ratio is presently 51.32%.
A number of analysts recently commented on the company. Atlantic Securities reiterated a “buy” rating and set a $54.00 price target on shares of Pfizer in a report on Tuesday, November 27th. Credit Suisse Group set a $42.00 target price on Pfizer and gave the stock a “hold” rating in a research report on Monday, November 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research report on Monday, November 19th. Citigroup lifted their price target on Pfizer from $34.00 to $37.00 and gave the company a “sell” rating in a research report on Tuesday, November 6th. Finally, BMO Capital Markets cut Pfizer from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $47.00 to $46.00 in a research report on Thursday, November 1st. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have assigned a buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $43.27.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/12/06/signature-financial-management-inc-sells-7205-shares-of-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: What is Liquidity?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.